206 related articles for article (PubMed ID: 32886320)
61. Fentanyl titration for cancer pain: continuous subcutaneous injection and a once-daily transdermal patch - case series.
Sakaguchi T; Kajiyama T; Miyake M; Katayama T
BMJ Support Palliat Care; 2024 Jan; 13(e3):e812-e815. PubMed ID: 35534185
[TBL] [Abstract][Full Text] [Related]
62. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain.
Christie JM; Simmonds M; Patt R; Coluzzi P; Busch MA; Nordbrock E; Portenoy RK
J Clin Oncol; 1998 Oct; 16(10):3238-45. PubMed ID: 9779697
[TBL] [Abstract][Full Text] [Related]
63. Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain.
Minkowitz H; Bull J; Brownlow RC; Parikh N; Rauck R
Support Care Cancer; 2016 Jun; 24(6):2669-75. PubMed ID: 26780504
[TBL] [Abstract][Full Text] [Related]
64. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K
Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190
[TBL] [Abstract][Full Text] [Related]
65. Indication of Adequate Transdermal Fentanyl Dose in Opioid Switching From Oral Oxycodone in Patients With Cancer.
Matsumura C; Yamada M; Fujihara S; Chisaki Y; Takahashi K; Yano Y
Am J Hosp Palliat Care; 2016 Mar; 33(2):109-14. PubMed ID: 25324418
[TBL] [Abstract][Full Text] [Related]
66. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).
Coluzzi PH; Schwartzberg L; Conroy JD; Charapata S; Gay M; Busch MA; Chavez J; Ashley J; Lebo D; McCracken M; Portenoy RK
Pain; 2001 Mar; 91(1-2):123-30. PubMed ID: 11240084
[TBL] [Abstract][Full Text] [Related]
67. Transdermal fentanyl system plus im ketorolac for the treatment of postoperative pain.
Reinhart DJ; Goldberg ME; Roth JV; Dua R; Nevo I; Klein KW; Torjman M; Vekeman D
Can J Anaesth; 1997 Apr; 44(4):377-84. PubMed ID: 9104519
[TBL] [Abstract][Full Text] [Related]
68. Effect of local administration of transdermal fentanyl on peripheral opioid analgesia.
Worrich S; Schuler G; Janicki PK
Pain Med; 2007; 8(1):41-7. PubMed ID: 17244103
[TBL] [Abstract][Full Text] [Related]
69. [Research from the Palliative Care Department in Poznań on treatment of neoplasm pain with Durogesic (transdermal fentanyl)].
Leppert W; Luczak J; Gorzelińska L; Kozikowska J
Przegl Lek; 2000; 57(1):59-64. PubMed ID: 10907375
[TBL] [Abstract][Full Text] [Related]
70. Transdermal fentanyl in the management of children with chronic severe pain: results from an international study.
Finkel JC; Finley A; Greco C; Weisman SJ; Zeltzer L
Cancer; 2005 Dec; 104(12):2847-57. PubMed ID: 16284992
[TBL] [Abstract][Full Text] [Related]
71. Risk Factors for Poor Pain Control after Opioid Switching from Oxycodone Tablet to Fentanyl Patch.
Morikawa N; Kasahara Y; Takahashi Y; Nishikura K; Nishihara M
Biol Pharm Bull; 2019; 42(10):1674-1678. PubMed ID: 31582655
[TBL] [Abstract][Full Text] [Related]
72. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain.
Allan L; Richarz U; Simpson K; Slappendel R
Spine (Phila Pa 1976); 2005 Nov; 30(22):2484-90. PubMed ID: 16284584
[TBL] [Abstract][Full Text] [Related]
73. The analgesic effect of rescue administration of intravenous acetaminophen in cancer patients may be associated with sex and opioid dose, and the effect would appear to patients administered under 45 mg/day opioid (oral morphine equivalents).
Niki K; Okamoto Y; Nakajima S; Uejima E
Pharmazie; 2018 Mar; 73(3):161-164. PubMed ID: 29544564
[TBL] [Abstract][Full Text] [Related]
74. [Opioid induction using rapid release drugs and the shift to fentanyl patches].
Sasaki S; Morohashi T; Otsuka Y; Ejima M; Tsujikawa Y; Yoshimura K; Terai E; Suzuki N; Nakayama H; Watanabe T
Gan To Kagaku Ryoho; 2014 Jul; 41(7):863-7. PubMed ID: 25131873
[TBL] [Abstract][Full Text] [Related]
75. Pharmacokinetic study between a bilayer matrix fentalyl patch and a monolayer matrix fentanyl patch: single dose administration in healthy volunteers.
Zecca E; Manzoni A; Centurioni F; Farina A; Bonizzoni E; Seiler D; Perrone T; Caraceni A
Br J Clin Pharmacol; 2015 Jul; 80(1):110-5. PubMed ID: 25612845
[TBL] [Abstract][Full Text] [Related]
76. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
[TBL] [Abstract][Full Text] [Related]
77. [Efficacy and safety of transdermal fentanyl patches for opioid initiation in patients with gastrointestinal obstruction].
Miyoshi T; Yamauchi H; Misumi N; Goto T; Kai S; Yoshida E; Nishino T; Hasuo Y
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1401-5. PubMed ID: 25434443
[TBL] [Abstract][Full Text] [Related]
78. Treatment of cancer pain with transdermal fentanyl.
Gourlay GK
Lancet Oncol; 2001 Mar; 2(3):165-72. PubMed ID: 11902567
[TBL] [Abstract][Full Text] [Related]
79. A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl.
Kornick CA; Santiago-Palma J; Khojainova N; Primavera LH; Payne R; Manfredi PL
Cancer; 2001 Dec; 92(12):3056-61. PubMed ID: 11753984
[TBL] [Abstract][Full Text] [Related]
80. A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain.
Sloan PA; Moulin DE; Hays H
J Pain Symptom Manage; 1998 Aug; 16(2):102-11. PubMed ID: 9737101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
